Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 55 points (0.3%) at 16,661 as of Tuesday, May 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,943 issues advancing vs. 1,024 declining with 173 unchanged.

The Health Care sector currently sits up 1.4% versus the S&P 500, which is up 0.5%. On the negative front, top decliners within the sector include

Edwards Lifesciences

(

EW

), down 2.2%,

AstraZeneca

(

AZN

), down 1.0%,

Baxter International

(

BAX

), down 0.7% and

Thermo Fisher Scientific

(

TMO

), down 0.5%. Top gainers within the sector include

Isis Pharmaceuticals

(

ISIS

), up 7.7%,

Alnylam Pharmaceuticals

(

ALNY

), up 6.0%,

Incyte

(

INCY

), up 3.1%,

Vertex Pharmaceuticals

(

VRTX

), up 2.6% and

Biogen Idec

(

BIIB

), up 1.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Perrigo

(

PRGO

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Perrigo is down $1.18 (-0.8%) to $137.45 on average volume. Thus far, 512,938 shares of Perrigo exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $137.23-$140.01 after having opened the day at $139.91 as compared to the previous trading day's close of $138.63.

Perrigo is buying Canam Care as of Jan 2012 for $36. Perrigo has a market cap of $18.5 billion and is part of the drugs industry. Shares are down 9.7% year-to-date as of the close of trading on Friday. Currently there are 12 analysts that rate Perrigo a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Perrigo

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Perrigo Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

Valeant Pharmaceuticals International

(

VRX

) is down $4.25 (-3.2%) to $129.21 on heavy volume. Thus far, 2.6 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $128.09-$132.99 after having opened the day at $132.80 as compared to the previous trading day's close of $133.46.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $44.7 billion and is part of the drugs industry. Shares are up 13.7% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Valeant Pharmaceuticals International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full

Valeant Pharmaceuticals International Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Allergan

(

AGN

) is down $2.81 (-1.7%) to $164.11 on average volume. Thus far, 1.9 million shares of Allergan exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $163.45-$167.75 after having opened the day at $167.24 as compared to the previous trading day's close of $166.92.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $49.7 billion and is part of the drugs industry. Shares are up 50.3% year-to-date as of the close of trading on Friday. Currently there are 6 analysts that rate Allergan a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Allergan

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Allergan Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null